Castle Biosciences (CSTL) Other Accumulated Expenses (2018 - 2026)

Castle Biosciences has reported Other Accumulated Expenses for 9 years, with the latest figure at $14.1 million in Q2 2026.

• Quarterly Other Accumulated Expenses rose 71.68% year-over-year to $14.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $14.1 million (up 71.68% YoY) and the FY2025 annual result came in at $8.9 million, up 11.81% from the prior year.
• Other Accumulated Expenses rose to $14.1 million in Q2 2026 per CSTL's latest filing, from $10.7 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $14.1 million in Q2 2026 and troughed at $5.1 million in Q3 2022.
• A 5-year average of $7.8 million and a median of $7.7 million in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses jumped 223.84% in 2022, then retreated 10.51% in 2023.
• Over 5 years, Other Accumulated Expenses stood at $5.3 million in 2022, then jumped by 39.05% to $7.3 million in 2023, then increased by 9.24% to $8.0 million in 2024, then grew by 11.81% to $8.9 million in 2025, then soared by 57.93% to $14.1 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $14.1 million, $10.7 million, and $8.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.